UnknownPhase 3

Treatment of Asymptomatic Toxocariasis With Albendazole in Children

Argentina45 participantsStarted 2008-09

Plain-language summary

The purpose of this study is to evaluate effectiveness of albendazole in the treatment of the asymptomatic infection with the parasite Toxocara in children. Treatment response is defined as a reduction in the number of eosinophils in blood. The study drug will be compared to placebo and randomly assigned in a double blind manner. Follow up will be prospective. 50 children (25 per group) will be enrolled in the study.

Who can participate

Age range2 Years – 15 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Pediatric ambulatory patients with asymptomatic toxocariasis * Children 2 - 15 years old * Absolute eosinophil count \> 1100 / mm3 * Normal ophthalmoscopy Exclusion Criteria: * Treatment with a benzimidazole in the previous year * Infection by other nematodes (Ascaris lumbricoides, strongyloides stercoralis, uncinarias, Trichuris trichuria) * Symptomatic patients (prolonged fever, acute pneumonitis, hepatomegaly, splenomegaly, ocular compromise due to toxocara) * Concomitant diseases * Immunocompromised patients * Altered liver or kidney function * Pregnancy

What they're measuring

Mean absolute reduction in eosinophil count from baseline

Timeframe: 12 months after treatment

Trial details

NCT IDNCT00755560

SponsorHospital de Niños R. Gutierrez de Buenos Aires

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2015-07

View on ClinicalTrials.gov More Toxocariasis trials